Jacobs serving as technical advisor as construction begins on New York State’s $1.7B public health laboratory
New facility will strengthen New York’s disease detection and public health response
DALLAS–(BUSINESS WIRE)–Jacobs (NYSE: J) is serving as the Dormitory Authority of the State of New York’s (DASNY) technical advisor for the progressive design-build project delivering the New York State Department of Health’s new Wadsworth Center Public Health Laboratory, an advanced public health laboratory in Albany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623964879/en/
The new facility will support highly specialized clinical, environmental and research activities.
The new 663,000 gross–square foot five-story laboratory will support highly specialized clinical, environmental and research activities. The planned new $1.7 billion Wadsworth Center will consolidate multiple laboratory sites into a single, modern campus, strengthening New York’s long-term public health readiness, research capacity and ability to respond to emerging biological and environmental threats.
Jacobs is providing consulting and technical advisory services across architectural, engineering and construction disciplines, representing DASNY and the New York State Department of Health while working with the design-build joint venture of Gilbane Building Company and Turner Construction Company, in association with HOK.
Jacobs Executive Vice President Imad Feghali said: “Large-scale public health laboratories demand rigorous technical oversight to support safety, reliability and adaptability over decades of operation. Jacobs’ independent technical advice is helping DASNY and the New York State Department of Health make informed decisions that advance regulatory compliance, operational resilience and long-term public health outcomes.”
The Wadsworth Center will fulfill a critical role in disease surveillance, outbreak response, environmental testing and newborn screening programs that protect communities in New York and beyond. The Wadsworth Center is a national reference laboratory recognized by the Centers for Disease Control and Prevention and other federal agencies. Construction is expected to be completed in 2030.
Around the world, Jacobs supports governments, healthcare providers and research institutions in planning and delivering complex health infrastructure and laboratory facilities. Engineering News-Record ranks Jacobs No. 1 in both healthcare and pharmaceuticals facilities. Jacobs has worked on more than 100 healthcare projects including the Johns Hopkins Medicine campus redevelopment in Baltimore, U.S., Christchurch Hospital in New Zealand and the Royal Prince Alfred Hospital redevelopment in Sydney.
At Jacobs, we’re challenging today to reinvent tomorrow – delivering outcomes and solutions for the world’s most complex challenges. With approximately $12 billion in annual revenue and a talent force of approximately 47,000, we provide end-to-end services in advanced manufacturing, cities & places, energy, environmental, life sciences, transportation and water. From advisory and consulting, feasibility, planning, design, program and lifecycle management, we’re creating a more connected and sustainable world. See how at jacobs.com and connect with us on LinkedIn, Instagram, X and Facebook.
Certain statements contained in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not directly relate to any historical or current fact. When used herein, words such as “expects,” “anticipates,” “believes,” “seeks,” “estimates,” “plans,” “intends,” “future,” “will,” “would,” “could,” “can,” “may,” and similar words are intended to identify forward-looking statements. We base these forward-looking statements on management’s current estimates and expectations, as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements including, but not limited to, uncertainties as to, the timing of the award of projects and funding and potential changes to the amounts provided for under the Infrastructure Investment and Jobs Act and other legislation and executive orders related to governmental spending, including any directive to federal agencies to reduce federal spending or the size of the federal workforce, and changes in U.S. or foreign tax laws, including the tax legislation enacted in the U.S. in July 2025, statutes, rules, regulations or ordinances, including the impact of, and changes to tariffs and retaliatory tariffs or trade policies, that may adversely impact our future financial positions or results of operations, as well as general economic conditions, including inflation and the actions taken by monetary authorities in response to inflation, changes in interest rates and foreign currency exchange rates, changes in capital markets, the possibility of a recession or economic downturn, and increased uncertainty and risks, including policy risks and potential civil unrest, relating to the outcome of elections across our key markets and elevated geopolitical tension and conflicts, among others. For a description of these and additional factors that may occur that could cause actual results to differ from our forward-looking statements, see our filings with the U.S. Securities and Exchange Commission. The company is not under any duty to update any of the forward-looking statements after the date of this press release to conform to actual results, except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260623964879/en/
For press/media inquiries:
[email protected]
KEYWORDS: Texas United States North America
INDUSTRY KEYWORDS: Biotechnology Urban Planning Construction & Property Other Health Health Pharmaceutical Research Infectious Diseases Hospitals Science Clinical Trials
MEDIA:
| Photo |
 |
| The new facility will support highly specialized clinical, environmental and research activities. |